PHARMALLY Business Summary

Pharmally International Holding Co., Ltd. (6452.TW) is a Taiwan-based pharmaceutical holding company that historically generated revenue through the production and sale of large-volume parenteral (LVP) injections and active pharmaceutical ingredients (APIs). Operating primarily through its manufacturing base in Mainland China, Six An Huayuan Pharmaceutical Co., Ltd., the company’s business segments included therapeutic LVP products (such as glucose and sodium chloride injections), API manufacturing (including nikethamide and levofloxacin lactate), and animal vaccines. However, the company was delisted from the Taiwan Stock Exchange on April 1, 2021, following a massive financial scandal and the disappearance of its chairman. Its primary direct competitors in the generic pharmaceutical and LVP markets included Sun Pharmaceutical Industries Ltd., Otsuka Holdings Co., Ltd., and Shenzhen Salubris Pharmaceuticals Co., Ltd., though Pharmally has effectively transitioned from a market participant to a defunct entity under legal liquidation as of 2026. As of March 2026, the company’s leadership remains defined by the legal aftermath of a NT$20.1 billion fraud case. Former Chairman Huang Wen-lie (Tony Huang), who founded the company in 2013, was arrested in Thailand in 2023 and sentenced by the Taipei District Court in June 2024 to 25 years in prison for securities fraud and embezzlement. Other key figures in the leadership team, including former Chairman Chen Min-lang, were also sentenced to multi-year prison terms in 2024. The company’s subsidiary operations in the Philippines were led by Huang Tzu Yen (Chairman), Twinkle Dargani (President), and Mohit Dargani (Treasurer), all of whom were central figures in a high-profile government procurement scandal. There is currently no active executive management team beyond court-appointed liquidators and legal representatives overseeing the settlement of claims by the Securities and Futures Investors Protection Center (SFIPC).